TME Pharma NV

ALTME

Company Profile

  • Business description

    TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).

  • Contact

    Max-Dohrn-Street 8-10
    Berlin10589
    DEU

    T: +49 307262470

    https://www.tmepharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    13

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,456.2090.501.08%
CAC 407,770.48176.612.33%
DAX 4023,086.65589.672.62%
Dow JONES (US)41,317.43564.471.39%
FTSE 1008,596.3599.551.17%
HKSE22,504.68385.271.74%
NASDAQ17,977.73266.991.51%
Nikkei 22536,830.69378.391.04%
NZX 50 Index12,327.89179.291.48%
S&P 5005,686.6782.531.47%
S&P/ASX 2008,238.0092.401.13%
SSE Composite Index3,279.037.62-0.23%

Market Movers